AbbVie (ABBV) announced the U.S. FDA has approved Rinvoq, 15 mg, once daily, for the treatment of adults with giant cell arteritis. This comes after the European Commission recently granted marketing authorization of Rinvoq for the treatment of GCA in adult patients.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $227 from $220 at Raymond James
- AbbVie price target raised to $204 from $200 at BofA
- AbbVie price target lowered to $205 from $230 at HSBC
- AbbVie: Strong Financial Performance and Growth Prospects Drive Positive Analyst Outlook
- AbbVie price target raised to $250 from $241 at Morgan Stanley